N-alpha-Acetylcarnosine is proposed for treatment of ocular disorders that have a component of oxidative stress in their genesis
Nalpha-acetylcarnosine is proposed as a prodrug of L-carnosine that is resistant to enzymatic hydrolysis by carnosinase with ability to give efficient protection against oxidative stress both in the lipid phase of biological membranes and in aqueous environments.
We now have a clearer understanding of the inflammatory processes involved in DED, and there is hope that the still emerging preclinical/clinical findings will be translated into new and highly effective therapies for patients in the near future.
Study finds that Dry Eye Disease (DED) progression may be delayed by breaking the chronic cycle of ocular surface inflammation
The purpose of this article is to review the evidence for the hypothesis that the core mechanism of Dry Eye Disease (DED) is inflammation, including evidence from recent basic, clinical and translational research involving human patients, animal models, and cell cultures.
Dry Eye type II is has been defined to be characterized by clinically-evident inflammation, and clear evidence of epithelial alterations. Type III Dry Eye is a chronic form with accompanied by clinically-evident and chronic inflammation.
Dry Eye Syndrome (DES) is a complex and often frustrating condition. If left unresolved it can lead to far more serious eye conditions. Fortunately, there are several ways to alleviate dry eye syndrome and reduce the risk of vision loss. In this article, we will discuss the causes, symptoms, avoidable risks, and treatments for dry eye syndrome.